^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RPL5 expression

    i
    Other names: RPL5, Ribosomal Protein L5, Protein Phosphatase 1, Regulatory Subunit 135, Large Ribosomal Subunit Protein UL18, 60S Ribosomal Protein L5, PPP1R135, UL18, MSTP030
    Entrez ID:
    6125
    over1year
    Ribosomal protein RPL5 regulates colon cancer cell proliferation and migration through MAPK/ERK signaling pathway. (PubMed, BMC Mol Cell Biol)
    RPL5 promoted colon cell proliferation and migration, at least in part, by activating the MAPK/ERK signaling pathway, which may serve as a novel therapeutic target for cancers in which MAPK/ERK signaling is a dominant feature.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MAP2K1 (Mitogen-activated protein kinase kinase 1) • FOXO3 (Forkhead box O3) • RPL5 (Ribosomal Protein L5)
    |
    MYC expression • RPL5 expression • MAP2K1 expression
    almost2years
    DDX24 promotes metastasis by regulating RPL5 in non-small cell lung cancer. (PubMed, Cancer Med)
    DDX24 acted as a pro-tumorigenic factor and promoted metastasis in NSCLC. DDX24 interacted with RPL5 to promote its ubiquitination and degradation. As a result, targeting DDX24/RPL5 axis may provide a novel potential therapeutic strategy for NSCLC.
    Journal
    |
    RPL5 (Ribosomal Protein L5)
    |
    RPL5 expression
    2years
    RPL15 promotes hepatocellular carcinoma progression via regulation of RPs-MDM2-p53 signaling pathway. (PubMed, Cancer Cell Int)
    RPL15 played crucial roles in HCC progression and metastasis, serving as a promising candidate for targeted therapies.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CCNE1 (Cyclin E1) • MDM2 (E3 ubiquitin protein ligase) • CDH1 (Cadherin 1) • BAX (BCL2-associated X protein) • VIM (Vimentin) • CDK2 (Cyclin-dependent kinase 2) • CDH2 (Cadherin 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • RPL5 (Ribosomal Protein L5)
    |
    CCNE1 expression • RPL5 expression • CDK2 expression
    3years
    The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. (PubMed, Cancers (Basel))
    Moreover, POMP was significantly up-regulated in MM patients refractory to bortezomib-based treatment. In multivariate analysis, high expression of PSMB5 and CXCR and autologous stem cell transplantation were independent predictors of progression-free survival, and high expression of POMP and RPL5 was associated with shorter overall survival.
    Clinical • Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • RPL5 (Ribosomal Protein L5) • XBP1 (X-box-binding protein 1)
    |
    RPL5 expression
    |
    bortezomib